Loading...
Little has been reported about the natural history of atopic dermatitis (AD). When topical calcineurin inhibitors were approved for AD treatment, the FDA required manufacturers to conduct post-marketing safety studies. One such effort is the Pediatric Eczema Elective Registry (PEER), which enrolled patients aged 2 to 17 years with mild-to-moderate AD who had used pimecrolimus cream for >42 days in the prior 6 months; they or their caretakers were mailed surveys every 6 months to log AD symptoms and treatment.
Investigators used survey responses to analyze AD persistence. At analysis, 7157 patients were enrolled; 4248 had at least 2 years of follow-up, and 2416 had at least 5 years' follow-up. Mean age at AD onset was 1.7 years; average age a…